NASDAQ · CRDL
Cardiol Therapeutics Inc. Class A
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CRDL: Nov 12, 2026
Cardiol Therapeutics Inc. Class A Common Shares is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.09.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.05 | $-0.05 | $-0.06 | 2 |
| Dec 2026 | $-0.05 | $-0.05 | $-0.06 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · MarketBeat · Fintel- Zacks · Sep 14, 9:30 AM EDT5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryINDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
- Zacks · Sep 10, 9:40 AM EDTIs Aspen Pharmacare (APNHY) Outperforming Other Medical Stocks This Year?Here is how Aspen Pharmacare (APNHY) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.
- RTTNews · Aug 27, 5:22 AM EDTBiotech Stocks At 52-Week Highs – CRDL, NEO, SPTX, RAPP, CGEM(RTTNews) – The following biotech stocks reached a 52-week high on August 26, 2026, as clinical trials continued enrolment and companies reached various regulatory milestones.
- RTTNews · Aug 26, 4:33 AM EDTBiotech Stocks At 52-Week Highs – GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7%(RTTNews) – The following biotech stocks reached a 52-week high on August 25, 2026, driven by key catalysts including positive clinical trial results or the issuance of quarterly reports.
- Zacks · Aug 25, 9:40 AM EDTIs Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?Here is how Cardiol Therapeutics Inc. (CRDL) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
- Zacks · Aug 24, 12:00 PM EDTCardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy?Does Cardiol Therapeutics Inc. (CRDL) have what it takes to be a top stock pick for momentum investors? Let's find out.
- MarketBeat · Aug 12, 8:01 AM EDTCardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial3 Penny Stocks Ready to Break Out in 2025Cardiol Therapeutics (NASDAQ:CRDL) is advancing its synthetic, pharmaceutical-grade cannabidiol formulation, CardiolRx, in a pivotal Phase III trial for recurrent pericarditis, with management describing the program as a key step toward a
- Zacks · Mar 3, 8:07 AM ESTPharming Group Gears Up to Report Q4 Earnings: What's in the Cards?PHAR heads into Q4 results, with Ruconest and Joenja sales in focus, pipeline updates looming, and investors eyeing clarity on key regulatory setbacks.
- Fintel · Dec 1, 7:05 PM ESTHC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy RecommendationFintel reports that on December 1, 2025, HC Wainwright & Co. reiterated coverage of Cardiol Therapeutics (NasdaqCM:CRDL) with a Buy recommendation. Analyst Price Forecast Suggests 647.10% Upside
- Zacks · Oct 15, 6:19 AM EDTZacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus TherapeuticsSmall-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.
- Zacks · Oct 14, 10:57 AM EDT5 Small Drug Stocks to Buy as the Industry Shows Some RecoveryInnovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
- RTTNews · Jul 22, 9:29 AM EDTCardiol To Report ARCHER Study Data Within The Next Two Weeks(RTTNews) – Cardiol Therapeutics Inc. (CRDL) is approaching a key clinical milestone related to its lead asset, CardiolRx.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Cardiol Therapeutics Inc. Class A from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.